Diffusion patterns of new anti-diabetic drugs into hospitals in Taiwan: The case of Thiazolidinediones for diabetes

BMC Health Services Research

Volumn 11, Issue , 2011, Pages

  Wen, Yu Wen ^a   Huang, Weng Foung ^b   Lee, Yue Chune ^b   Kuo, Ken N ^c   Tsai, Chia Rung ^c   Tsai, Yi Wen ^b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ARTICLE; DIABETES MELLITUS; HOSPITAL PHARMACY; HUMAN; MASS COMMUNICATION; PRESCRIPTION; PROPORTIONAL HAZARDS MODEL; STATISTICAL MODEL; STATISTICS; TAIWAN;

DIABETES MELLITUS; DIFFUSION OF INNOVATION; DRUG PRESCRIPTIONS; HUMANS; HYPOGLYCEMIC AGENTS; LOGISTIC MODELS; PHARMACY SERVICE, HOSPITAL; PROPORTIONAL HAZARDS MODELS; TAIWAN; THIAZOLIDINEDIONES;

EID: 79251554373     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-11-21     Document Type: Article

References (65)

1. Are medical prices declining? evidence from heart attack treatments. DM Cutler M McClellan JP Newhouse D Remler, The Quarterly Journal of Economics 1998 113 4 991 1024 10.1162/003355398555801
2. Health care for the elderly: two cases of technology diffusion. A Dozet CH (Pubitemid 33049871)
3. The health care quadrilemma: an essay on technological change, insurance, quality of care, and cost containment. BA Weisbrod, Journal of Economic Literature 1991 29 2 523 552
4. Product diffusion and the demand for new food products. Y Duval A Biere, Agribusiness 2002 18 1 23 36 10.1002/agr.10005
5. EM Rogers, Diffusion of Innovations New York: Simon & Schuster 5 2003
6. The innovation diffusion process in a heterogeneous population: a micromodeling approach. R Chatterjee J Eliashberg, Management Science 1990 36 9 1057 1079 10.1287/mnsc.36.9.1057
7. User acceptance of computer technology: a comparison of two theoretical models. FD Davis RP Bagozzi PR Warshaw, Management Science 1989 35 8 982 10.1287/mnsc.35.8.982
8. Systems competition and network effects. ML Katz C Shapiro, The Journal of Economic Perspectives 1994 8 2 93 115
9. A new product growth for model consumer durables. FM Bass, Management Science 1969 15 5 215 227 10.1287/mnsc.15.5.215
10. The future of research in marketing: marketing science. FM Bass, Journal of Marketing Research 1993 30 1 1 6 10.2307/3172509
11. Testing the HMO competitive strategy: An analysis of its impact on medical care resources. SC Hill BL Wolfe, Journal of Health Economics 1997 16 3 261 286 10.1016/S0167-6296(96)00538-3 10169301 (Pubitemid 27293311)
12. Managed care and technology adoption in health care: evidence from magnetic resonance imaging. LC Baker, Journal of Health Economics 2001 20 3 395 421 10.1016/S0167-6296(01)00072-8 11373838 (Pubitemid 32331840)
13. Managed care and technology diffusion: the case of MRI. LC Baker SK Wheeler, Health Affairs 1998 17 5 195 207 10.1377/hlthaff.17.5.195 9769583 (Pubitemid 128465532)
14. Diffusion of medical technology and equity in health in brazil: an exploratory analysis. S Loureiro B Simes E Arago F Mota H Moura L Damasceno, European Journal of Development Research 2007 19 1 66 80 10.1080/ 09578810601144319 (Pubitemid 46929235)
15. Managed care, technology adoption and health care: the adoption of neonatal intensive care. LC Baker CS Phibbs, RAND Journal of Economics 2002 33 3 524 548 10.2307/3087471 12585306
16. Managed care and medical technology: implications for cost growth. M Chernew AM Fendrick RA Hirth, Health Affairs 1997 16 2 196 206 10.1377/hlthaff.16.2.196 9086669 (Pubitemid 127464029)
17. Diffusion of six surgical endoscopic procedures in the Netherlands. stimulating and restraining factors. CD Dirksen AJH Ament PMN Go, Health Policy 1996 37 2 91 104 10.1016/S0168-8510(96)90054-8 10172857 (Pubitemid 26228439)
18. Diffusion of laparoscopic cholecystectomy among general surgeons in the United States. JJ Escarce BS Bloom AL Hillman JA Shea JS Schwartz, Medical Care 1995 33 3 256 271 10.1097/00005650-199503000-00005 7861828
19. Hospital sdoption of laparoscopic cholecystectomy. AM Fendrick JJ Escarce C McLane JA Shea JS Schwartz, Medical Care 1994 32 10 1058 1063 10.1097/00005650-199410000-00007 7934272
20. Diffusion of laparoscopic technologies in Denmark. PB Poulsen S Adamsen H Vondeling T Jorgensen, Health Policy 1998 45 2 149 167 10.1016/S0168-8510(98) 00036-0 10186225 (Pubitemid 29034609)
21. Timing of adoption of laparoscopic cholecystectomy in Denmark and in The Netherlands: a comparative study. PB Poulsen H Vondeling CD Dirksen S Adamsen PMNYH Go AJH Ament, Health Policy 2001 55 2 85 95 10.1016/S0168-8510(00)00123-8 11163648 (Pubitemid 32037120)
22. Managed care, information, and diffusion: the case of treatment for heart-attack patients. LC Baker CC Afendulis PA Heidenreich, American Economic Review 2004 94 2 347 351 10.1257/0002828041301768 (Pubitemid 39057116)
23. The diffusion of a medical innovation: is success in the Stars? MA Burke GM Fournier K Prasad, Southern Economic Journal 2007 73 3 588 603
24. Diffusion of innovations: treatment of Alzheimer's disease in Germany. J Ruof T Mittendorf O Pirk JM von der Schulenburg, Health Policy 2002 60 1 59 66 10.1016/S0168-8510(01)00191-9 11879945 (Pubitemid 34173629)
25. The diffusion of hospital technologies: some econometric evidence. LB Russell, The Journal of Human Resources 1977 12 4 482 502 10.2307/145371 338831
26. The determinants of technological change in heart attack treatment. DM Cutler M McClellan, NBER Working Paper #5751 Cambridge, MA 1996
27. Medical technology - a different view of the contentious debate over costs. TW Moloney DE Rogers, The New England journal of medicine 1979 301 26 1413 1419 10.1056/NEJM197912273012603 117359 (Pubitemid 10199235)
28. Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. FR Lichtenberg, Health Affairs 2001 20 5 241 251 10.1377/hlthaff.20.5.241 11558710 (Pubitemid 33710357)
29. Do new prescription drugs pay for themselves? The case of second-generation antipsychotics. M Duggan, Journal of Health Economics 2005 24 1 1 31 10.1016/j.jhealeco.2004.08.001 15617786 (Pubitemid 40023070)
30. An analysis of the diffusion of new antidepressants: variety, quality, and marketing efforts. ER Berndt A Bhattacharjya DN Mishol A Arcelus T Lasky, J Ment Health Policy Econ 2002 5 1 3 19 12529566 (Pubitemid 36054684)
31. The Diffusion of new antipsychotic medications and formulary policy. ME Domino RG Frank R Rosenheck, Schizophrenia Bulletin 2003 29 1 95 104 12908664 (Pubitemid 36871060)
32. Synergy between publication and promotion: comparing adoption of new evidence in Canada and the United States. SR Majumdar FA McAlister SB Soumerai, Am J Med 2003 155 6 467 72 10.1016/S0002-9343(03)00422-4 (Pubitemid 37237560)
33. Drug patent expirations and speed of generic entry. JP Bae, Health Services Research 1997 32 1 87 101 9108806 (Pubitemid 27172816)
34. Information, marketing, and pricing in the U.S. antiulcer drug market. ER Berndt L Bui DR Reiley GL Urban, American Economic Review 1995 85 2 100 105 10160519
35. Characteristics of demand for pharmaceutical products: an examination of four cephalosporins. SF Ellison I Cockburn Z Griliches J Hausman, The RAND Journal of Economics 1997 28 3 426 446 10.2307/2556023 11794359 (Pubitemid 127346460)
36. Competition and substitutability in the Swedish pharmaceuticals market. N Rudholm, Applied Economics 2003 35 14 1609 1617 10.1080/0003684032000125042 (Pubitemid 37388309)
37. Market size in innovation: theory and evidence from the pharmaceutical industry. D Acemoglu J Linn, Quarterly Journal of Economics 2004 119 3 1049 1090 10.1162/0033553041502144 (Pubitemid 39057314)
38. The impact of generic drug competition on brand name market shares - evidence from micro Data. T Aronsson MA Bergman N Rudholm, Review of Industrial Organization 2001 19 4 423 433 10.1023/A:1012504310953
39. Patent expiration, entry, and competition in the U.S. pharmaceutical industry. RE Caves MD Whinston MA Hurwitz, Brookings Papers on Economic Activity Microeconomics 1991 1991 1 66 10.2307/2534790
40. Pricing, patent loss and the market for pharmaceuticals. R Frank DS Salkever, Southern Economic Journal 1992 59 165 179 10.2307/1060523
41. Prescription drug prices: why do some pay more than others do? RG Frank, Health Affairs 2001 20 2 115 128 10.1377/hlthaff.20.2.115 11260933
42. Generic entry and the pricing of pharmaceuticals. RG Frank DS Salkever, Journal of Economics & Management Strategy 1997 6 1 75 90
43. Brand loyalty, entry and price competition in pharmaceuticals after the 1984 Drug Act. HG Grabowski JM Vernon, Journal of Law and Economics 1992 35 331 350 10.1086/467257
44. Pricing dynamics in the pharmaceutical industry. J Hudson, Applied Economics 1992 24 1 103 112 10.1080/00036849200000108
45. Entry decisions in the generic pharmaceutical industry. FMS Morton, The RAND Journal of Economics 1999 30 3 421 440 10.2307/2556056 10558596
46. Entry and the number of firms in the Swedish pharmaceuticals market. N Rudholm, Review of Industrial Organization 2001 19 3 351 364 10.1023/A:1011868404205 (Pubitemid 32974662)
47. Generic competition in the US pharmaceutical industry. A Saha H Grabowski H Birnbaum P Greenberg O Bizan, International Journal of the Economics of Business 2006 13 1 15 38 10.1080/13571510500519905 (Pubitemid 43443798)
48. An analysis of the diffusion of new antidepressants: variety, quality, and marketing efforts. ER Berndt A Bhattacharjya DN Mishol A Arcelus T Lasky, The Journal of Mental Health Policy and Economics 2002 5 1 3 19 12529566 (Pubitemid 36054684)
49. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. M Diamant RJ Heine, Drugs 2003 63 13 1373 1405 10.2165/00003495- 200363130-00004 12825962 (Pubitemid 36776093)
50. Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. FJ Cohen CA Neslusan JE Conklin X Song, Diabetes Care 2003 26 1847 1851 10.2337/diacare.26.6.1847 12766121 (Pubitemid 36929131)
51. Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001. DK Wysowski G Armstrong L Governale, Diabetes Care 2003 26 1852 1855 10.2337/diacare.26.6.1852 12766122 (Pubitemid 36929132)
52. BNHI, Report on Healthcare Quality in Diabetes Mellitus Taipei: Bureau of National Health Insurance 2003
53. BNHI, National Health Insurance Statistics Report Taipei: Bureau of National Health Insurance 2008
54. Pharmaceutical penetration of new drug and pharmaceutical market structure: Hospital-level prescription of Thiazolidinediones for Diabetes. YW Tsai YW Wen WF Huang KN Kuo PF Chen HW Shih YC Lee, European Journal of Health Economics 2010 11 3 279 290 10.1007/s10198-009-0174-1 19649666
55. The WHO Collaborating Centre for Drug Statistics Methodology, http://www.whocc.no/
56. Regression Quantiles. R Koenker Bassett Gilbert Jr, Econometrica 1978 46 1 33 50 10.2307/1913643
57. The potentially inappropriate prescription of new drug: Thiazolidinediones for patients with type II diabetes in Taiwan. YW Wen YW Tsai WF Huang FY Hsiao PF Chen, Pharmacoepidemiology and Drug Safety 2010
58. Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting. S Maru GG Koch M Stender D Clark L Gibowski H Petri AD White RJ Simpson Jr, Diabetes Care 2005 28 20 26 10.2337/diacare.28.1.20 15616228 (Pubitemid 40095777)
59. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: A retrospective cohort study. TE Delea JS Edelsberg M Hagiwara G Oster LS Phillips, Diabetes Care 2003 26 2983 2989 10.2337/diacare.26.11.2983 14578227 (Pubitemid 37339487)
60. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. R Rajagopalan RS Rosenson AW Fernandes M Khan FT Murray, Clin Ther 2004 26 1400 1410 10.1016/j.clinthera. 2004.09.016 15531002 (Pubitemid 39572154)
61. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. AJ Karter AT Ahmed J Liu HH Moffet MM Parker, Diabet Med 2005 22 986 993 10.1111/j.1464-5491.2005.01704.x 16026362 (Pubitemid 41025993)
62. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: An observational study. FA Masoudi SE Inzucchi Y Wang EP Havranek JM Foody HM Krumholz, Circulation 2005 111 583 590 10.1161/01.CIR.0000154542.13412.B1 15699279 (Pubitemid 40216485)
63. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. DREAM, Lancet 2006 368 1096 1105 10.1016/S0140-6736(06)69420-8 16997664
64. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. JA Dormandy B Charbonnel DJ Eckland E Erdmann M Massi-Benedetti IK Moules AM Skene MH Tan PJ Lefèbvre GD Murray E Standl RG Wilcox L Wilhelmsen J Betteridge K Birkeland A Golay RJ Heine L Kornyi M Laakso M Mokn A Norkus V Pirags T Podar A Scheen W Scherbaum G Schernthaner O Schmitz J Skrha U Smith J Taton PROactive investigators, Lancet 2005 366 1279 1289 10.1016/S0140-6736(05)67528-9 16214598 (Pubitemid 41416583)
65. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. SE Nissen K Wolski, N Engl J Med 2007 356 24 2457 2471 10.1056/NEJMoa072761 17517853 (Pubitemid 46919772)